Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -117.04% is 44% above its 5-year average of -207.68%, near the high end of its 5-year range (-167476.92%–65.63%).
99.80% above its 12-month average of -59650.98%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-117.04%
NET PROFIT MARGIN AVG TTM
-59650.98%
NET PROFIT MARGIN AVG 3Y
-604.76%
NET PROFIT MARGIN AVG 5Y
-207.68%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.80%
CURRENT VS 3Y AVG
+80.65%
CURRENT VS 5Y AVG
+43.64%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Precision BioSciences, Inc.
Market Cap
$173.98M
Net Profit Margin
-117.04%
TTM Avg
-59650.98%
3Y Avg
-604.76%
5Y Avg
-207.68%
Market Cap
$173.79M
Net Profit Margin
-435.83%
TTM Avg
-267.41%
3Y Avg
-1429.19%
5Y Avg
-1238.68%
Market Cap
$173.23M
Net Profit Margin
-229.20%
TTM Avg
-206.03%
3Y Avg
-659.07%
5Y Avg
-1951.89%
Market Cap
$176.36M
Net Profit Margin
0.00%
TTM Avg
-2904.41%
3Y Avg
-1452.20%
5Y Avg
-968.14%
Market Cap
$171.62M
Net Profit Margin
-170.10%
TTM Avg
-145.13%
3Y Avg
-100.04%
5Y Avg
-83.24%
Market Cap
$169.85M
Net Profit Margin
-19.76%
TTM Avg
3.38%
3Y Avg
2.83%
5Y Avg
6.10%
Market Cap
$178.44M
Net Profit Margin
-8.95%
TTM Avg
-22.31%
3Y Avg
-22.43%
5Y Avg
-24.59%
Market Cap
$166.35M
Net Profit Margin
4.66%
TTM Avg
-8.57%
3Y Avg
-15.00%
5Y Avg
-10.75%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Precision BioSciences, Inc. (DTIL) | $173.98M | -117.04% | -59650.98% | -604.76% | -207.68% |
| Cue Biopharma, Inc. (CUE)vs › | $173.79M | -435.83% | -267.41% | -1429.19% | -1238.68% |
| Nkarta, Inc. (NKTX)vs › | $173.50M | 0.00% | 0.00% | 0.00% | 0.00% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.23M | -229.20% | -206.03% | -659.07% | -1951.89% |
| Compass Therapeutics, Inc. (CMPX)vs › | $176.36M | 0.00% | -2904.41% | -1452.20% | -968.14% |
| MediWound Ltd. (MDWD)vs › | $171.62M | -170.10% | -145.13% | -100.04% | -83.24% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | -19.76% | 3.38% | 2.83% | 6.10% |
| Journey Medical Corporation (DERM)vs › | $178.44M | -8.95% | -22.31% | -22.43% | -24.59% |
| OptimizeRx Corp. (OPRX)vs › | $166.35M | 4.66% | -8.57% | -15.00% | -10.75% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $182.12M | 3202.50% | 1601.25% | 554.42% | 279.00% |
Operating Margin
-152.2%
Net Profit Margin
-117.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | -170.15% |
| 2025-12-31 | 58.86% |
| 2025-09-30 | -167476.92% |
| 2025-06-30 | -130666.67% |
| 2025-03-31 | -70913.79% |
| 2024-12-31 | -2781.35% |
| 2024-09-30 | -2851.56% |
| 2024-06-30 | 65.63% |
| 2024-03-31 | 48.84% |
| 2023-12-31 | -231.44% |
| 2023-09-30 | -125.95% |
| 2023-06-30 | -60.45% |
| 2023-03-31 | -285.42% |
| 2022-12-31 | -268.81% |
| 2022-09-30 | -325.22% |
| 2022-06-30 | -812.43% |
| 2022-03-31 | -849.20% |
| 2021-12-31 | -351.63% |
| 2021-09-30 | -46.93% |
| 2021-06-30 | 31.47% |
| 2021-03-31 | -114.31% |
| 2020-12-31 | -265.13% |
| 2020-09-30 | -353.33% |
| 2020-06-30 | -3033.49% |
| 2020-03-31 | -383.48% |
| 2019-12-31 | -320.70% |
| 2019-09-30 | -426.35% |
| 2019-06-30 | -360.66% |
| 2019-03-31 | -581.89% |
| 2018-12-31 | -312.61% |
| 2018-09-30 | -383.94% |
| 2018-06-30 | -631.06% |
| 2018-03-31 | -589.79% |
